This was the stock's second consecutive day of losses.

What Happened? A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5% ...

Lecanemab was approved in the U.S. in 2023 as the world's first drug to slow the cognitive decline associated with Alzheimer's. The treatment also has received approval in Japan, China, Europe and ...

Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines ...

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...

Searching For Answers C-Suite Leaders Awards The San Francisco Business Times is now seeking nominations for our annual C-Suite Leaders Awards, which highlights leading local executives and their ...

Biogen Inc. closed 47.73% short of its 52-week high of $238.00, which the company reached on July 12th.

Biogen appointed multiple co-lead underwriters for two fixed-income offerings totaling over $1 billion, showcasing its efforts to bolster financial offerings. This move, coupled with Biogen's ...

Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment.

Biogen Inc.'s earnings and share price have declined due to falling Multiple Sclerosis treatment revenue; new drugs and pipeline show promise but haven't offset losses yet. Biogen's Multiple ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...